WallStreetZenWallStreetZen

NASDAQ: CLYM
Climb Bio Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for CLYM

Based on 4 analysts offering 12 month price targets for Climb Bio Inc

Min Forecast
$8.00+314.51%
Avg Forecast
$9.00+366.32%
Max Forecast
$10.00+418.13%

Should I buy or sell CLYM stock?

Based on 4 analysts offering ratings for Climb Bio Inc.

Strong Buy
Strong Buy
1 analysts 25%
Buy
3 analysts 75%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although CLYM's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates CLYM as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their CLYM stock forecasts and price targets.

CLYM stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-10-16
lockedlocked$00.00+00.00%2025-10-13
lockedlocked$00.00+00.00%2025-08-15
lockedlocked$00.00+00.00%2025-06-06

1 of 1

Forecast return on equity

Is CLYM forecast to generate an efficient return?

Company
-44.99%
Industry
96.93%
Market
-62.31%
CLYM's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is CLYM forecast to generate an efficient return on assets?

Company
-43.44%
Industry
35.83%
CLYM is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

CLYM earnings per share forecast

What is CLYM's earnings per share in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
-$0.76
Avg 2 year Forecast
-$0.80
Avg 3 year Forecast
-$0.95

CLYM revenue forecast

What is CLYM's revenue in the next 2 years based on estimates from 1 analyst?

Avg 1 year Forecast
$42.0M
Avg 2 year Forecast
$316.8M

CLYM vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
CLYM$1.93$9.00+366.32%Strong Buy
GLSI$9.49$39.00+310.96%Buy
CNTX$1.44$5.50+281.94%Strong Buy
TIL$19.09$125.00+554.96%Buy
CGTX$1.74$3.50+101.15%Strong Buy
View Top Biotech Stocks

Climb Bio Stock Forecast FAQ

Is Climb Bio Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 4 Wall Street analysts covering (NASDAQ: CLYM) stock is to Strong Buy CLYM stock.

Out of 4 analysts, 1 (25%) are recommending CLYM as a Strong Buy, 3 (75%) are recommending CLYM as a Buy, 0 (0%) are recommending CLYM as a Hold, 0 (0%) are recommending CLYM as a Sell, and 0 (0%) are recommending CLYM as a Strong Sell.

If you're new to stock investing, here's how to buy Climb Bio stock.

What is CLYM's earnings growth forecast for 2025-2027?

(NASDAQ: CLYM) Climb Bio's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 4.13%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 16.01%.

Climb Bio's earnings in 2025 is -$46,758,000.On average, 4 Wall Street analysts forecast CLYM's earnings for 2025 to be -$51,500,716, with the lowest CLYM earnings forecast at -$53,533,639, and the highest CLYM earnings forecast at -$48,790,152. On average, 4 Wall Street analysts forecast CLYM's earnings for 2026 to be -$53,872,460, with the lowest CLYM earnings forecast at -$63,020,613, and the highest CLYM earnings forecast at -$44,724,306.

In 2027, CLYM is forecast to generate -$64,599,517 in earnings, with the lowest earnings forecast at -$69,119,382 and the highest earnings forecast at -$59,632,408.

What is CLYM's revenue growth forecast for 2030-2031?

(NASDAQ: CLYM) Climb Bio's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 90.96%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 11.86%.

Climb Bio's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast CLYM's revenue for 2030 to be $2,846,092,200, with the lowest CLYM revenue forecast at $2,846,092,200, and the highest CLYM revenue forecast at $2,846,092,200.

In 2031, CLYM is forecast to generate $21,467,666,880 in revenue, with the lowest revenue forecast at $21,467,666,880 and the highest revenue forecast at $21,467,666,880.

What is CLYM's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: CLYM) forecast ROA is -43.44%, which is lower than the forecast US Biotechnology industry average of 35.83%.

What is CLYM's Price Target?

According to 4 Wall Street analysts that have issued a 1 year CLYM price target, the average CLYM price target is $9.00, with the highest CLYM stock price forecast at $10.00 and the lowest CLYM stock price forecast at $8.00.

On average, Wall Street analysts predict that Climb Bio's share price could reach $9.00 by Oct 16, 2026. The average Climb Bio stock price prediction forecasts a potential upside of 366.32% from the current CLYM share price of $1.93.

What is CLYM's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: CLYM) Climb Bio's current Earnings Per Share (EPS) is -$0.53. On average, analysts forecast that CLYM's EPS will be -$0.76 for 2025, with the lowest EPS forecast at -$0.79, and the highest EPS forecast at -$0.72. On average, analysts forecast that CLYM's EPS will be -$0.80 for 2026, with the lowest EPS forecast at -$0.93, and the highest EPS forecast at -$0.66. In 2027, CLYM's EPS is forecast to hit -$0.95 (min: -$1.02, max: -$0.88).

What is CLYM's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: CLYM) forecast ROE is -44.99%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.